Divis Laboratories Ltd (DIVISLAB)
₹9,271.50
Mkt cap
₹2.42L Cr
P/E ratio
81.10
P/B
14.69
Div yield
0.33%
ROE
16.50%
ROCE
22.00%
EPS (TTM)
₹114.32
Book value
₹631
52W range
5,690–9,467
Sector
Healthcare
Price history
Previous close
Incorporated in 1990, Divis Laboratories Ltd manufactures and exports API's, Intermediates and Nutraceutical ingredients [1]
NSE DIVISLABBSE 532488
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthModerate
TechnicalsBullish
52-week range
−2.07% from high₹9,272
₹5,690+62.96% from low₹9,467
Current
₹9,271.50
Prev close
₹9,100.00
Day
+1.88%
Price performance
1D
+1.88%
1W
−2.07%
1M
+12.04%
3M
+37.29%
6M
+46.79%
1Y
+52.17%
YTD
+45.04%
Financials
Revenue, profit & margin
P/E ratio
81.1×
DIVISLAB is 139% above the sector median of 34.0×
DIVISLAB81.1×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,778 | 1,909 | 1,855 | 2,303 | 2,118 | 2,338 | 2,319 | 2,585 | 2,410 | 2,715 | 2,604 | 2,831 | 3,080 | |
| Expenses | 1,274 | 1,430 | 1,366 | 1,572 | 1,496 | 1,622 | 1,576 | 1,699 | 1,681 | 1,827 | 1,714 | 1,897 | 1,825 | |
| Operating Profit | 504 | 479 | 489 | 731 | 622 | 716 | 743 | 886 | 729 | 888 | 890 | 934 | 1,255 | |
| OPM % | 28% | 25% | 26% | 32% | 29% | 31% | 32% | 34% | 30% | 33% | 34% | 33% | 41% | |
| Other Income | 81 | 86 | 95 | 79 | 79 | 106 | 82 | 86 | 119 | 145 | 14 | 155 | 64 | |
| Interest | 0 | 1 | 0 | 2 | 0 | 1 | 0 | 1 | 3 | 8 | 6 | 6 | 6 | |
| Depreciation | 93 | 95 | 95 | 95 | 97 | 99 | 99 | 107 | 112 | 113 | 118 | 120 | 133 | |
| Profit before tax | 492 | 469 | 489 | 713 | 604 | 722 | 726 | 864 | 733 | 912 | 780 | 963 | 1,180 | |
| Tax % | 28% | 26% | 27% | 25% | 29% | 29% | 19% | 23% | 26% | 24% | 25% | 22% | 24% | |
| Net Profit | 356 | 348 | 358 | 538 | 430 | 510 | 589 | 662 | 545 | 689 | 583 | 751 | 902 | |
| EPS in Rs | 13.41 | 13.11 | 13.49 | 20.27 | 16.20 | 19.21 | 22.19 | 24.94 | 20.53 | 25.95 | 21.96 | 28.29 | 33.98 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.20% · closed higher next day 29 of last 62
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26† | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 14 Aug '23◦ | 6 Nov '23◦ | 10 Feb '24◦ | 25 May '24◦ | 3 Aug '24◦ | 9 Nov '24◦ | 3 Feb '25◦ | 17 May '25◦ | 6 Aug '25 | 7 Nov '25 | 11 Feb '26 | 23 May '26◦ |
| Earnings day | −0.49% | −0.72% | +2.41% | +3.22% | −3.29% | −0.84% | +3.61% | +4.79% | −4.30% | −3.30% | +3.42% | −1.89% |
| +1 day | −2.03% | −0.45% | +1.32% | +6.54% | −3.28% | −2.34% | +4.07% | +2.75% | −4.33% | −2.79% | +0.15% | −1.95% |
| +5 days | −0.71% | +0.86% | +1.95% | +4.84% | −2.01% | −0.82% | +1.06% | +7.29% | −4.81% | −5.40% | +1.75% | −5.14% |
| +15 days | −0.61% | +8.04% | −4.65% | +10.72% | −1.78% | +5.15% | −2.68% | +5.63% | −4.33% | −5.91% | +3.06% | −2.53% |
| +30 days | −1.76% | +3.59% | −7.79% | +10.42% | +9.24% | −1.06% | −1.05% | +8.44% | −3.26% | −5.88% | −2.88% | −1.92% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 30 Per Share | 30.00 | 24 Jul '26 | 24 Jul '26 |
Results analysis
Shareholding
as of Jun 202651.88%Promoter
Promoters51.88%
FIIs20.19%0.10
DIIs19.29%0.16
Public8.53%0.08
Government0.09%
Ownership trend
Peers
7 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013nseAnnual Report 2013bse
Concall transcripts37
TranscriptAug 2026RECAug 2026TranscriptMay 2026TranscriptFeb 2026RECFeb 2026TranscriptNov 2025RECNov 2025TranscriptAug 2025TranscriptMay 2025TranscriptFeb 2025RECFeb 2025TranscriptNov 2024RECNov 2024TranscriptAug 2024RECAug 2024TranscriptMay 2024RECMay 2024RECMay 2024TranscriptFeb 2024RECFeb 2024TranscriptNov 2023TranscriptNov 2023TranscriptAug 2023RECAug 2023
Credit ratings5
Announcements5
Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 10 AugShareholder Meeting / Postal Ballot-Outcome of AGM 10 Aug - 36th AGM held Aug 10, 2026; all resolutions passed, including ₹30 dividend per share.Announcement under Regulation 30 (LODR)-Earnings Call Transcript 6 Aug - Submission of transcript of Earnings Conference Call held on August 01, 2026Announcement under Regulation 30 (LODR)-Newspaper Publication 3 Aug - Newspaper clippings regarding unaudited financial results of the Company for the quarter ended June 30, 2026Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome 1 Aug - Q1 FY27 earnings call audio recording uploaded on August 1, 2026.